Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT1) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.
Kjeldsen
Sverre E
SE
Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway. s.e.kjeldsen@medisin.uio.no
Lyle
Paulette A
PA
Kizer
Jorge R
JR
Oparil
Suzanne
S
Høieggen
Aud
A
Os
Ingrid
I
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000503:physiopathology / Q000517:prevention & control*
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D019808:Losartan
JAMA. 2003 Jul 9;290(2):199-206
12851274
J Hypertens. 2003 Aug;21(8):1563-74
12872052
Circulation. 2003 Aug 12;108(6):684-90
12885747
Clin Ther. 2001 Aug;23(8):1166-79
11558856
Lancet. 2001 Sep 29;358(9287):1033-41
11589932
Manag Care. 2000 Sep;9(9 Suppl):2-6
11729417
Am J Hypertens. 2006 May;19(5):439-42
16647610
Stroke. 2006 Jun;37(6):1583-633
16675728
Eur Heart J. 2006 Jul;27(14):1651-6
16603580
Clin Ther. 2006 Oct;28(10):1639-48
17157119
Circulation. 2007 Feb 6;115(5):e69-171
17194875
Curr Med Res Opin. 2007 Feb;23(2):259-70
17288679
Curr Med Res Opin. 2007 Feb;23(2):443-57
17288698
Hypertension. 2001 Dec 1;38(6):E28-32
11751742
N Engl J Med. 2000 Jan 20;342(3):145-53
10639539
Am J Hypertens. 2000 Jan;13(1 Pt 1):103-4
10678279
Circulation. 2000 Apr 11;101(14):1653-9
10758046
Cochrane Database Syst Rev. 2000;(2):CD000028
10796688
Blood Press. 2001;10(4):190-2
11800055
J Hypertens. 2002 Apr;20(4):779-84
11910316
Lancet. 2002 Mar 23;359(9311):995-1003
11937178
Circ Res. 2002 Apr 19;90(7):754-6
11964366
Clin Ther. 2002 Jul;24(7):1049-61
12182251
J Hypertens. 2002 Sep;20(9):1879-86
12195132
Kidney Int. 2004 Mar;65(3):1041-9
14871425
J Am Coll Cardiol. 2004 Mar 17;43(6):1047-55
15028365
Expert Rev Cardiovasc Ther. 2003 May;1(1):43-50
15030296
Lancet. 2004 Jun 19;363(9426):2022-31
15207952
Clin Ther. 2004 May;26(5):631-48
15220009
Lancet. 2004 Jul 31-Aug 6;364(9432):413; author reply 413-4
15288732
J Hypertens. 2004 Sep;22(9):1805-11
15311110
Circulation. 2004 Sep 14;110(11):1456-62
15326072
Hypertension. 2004 Oct;44(4):398-404
15326093
Clin Exp Hypertens. 1980;2(3-4):639-57
6253243
J Cardiovasc Pharmacol. 1985;7 Suppl 1:S52-5
2580177
Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):531-4
3103761
Kidney Int. 1987 Mar;31(3):815-9
3033389
J Clin Hypertens. 1987 Sep;3(3 Suppl):108S-113S
3312505
Am J Cardiol. 1988 Jun 15;61(16):41H-45H
3289350
J Cardiovasc Pharmacol. 1989 Feb;13(2):314-9
2468963
Nephron. 1990;55 Suppl 1:70-2
2345592
Stroke. 1991 Mar;22(3):312-8
2003301
Stroke. 1992 Nov;23(11):1551-5
1440701
J Hypertens Suppl. 1993 Apr;11(3):S37-42
8315518
Hypertension. 1995 May;25(5):1042-4
7737713
Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13
9234823
Lancet. 1998 Oct;352 Suppl 3:SIII1-4
9803954
Hypertension. 1998 Dec;32(6):989-97
9856962
Lancet. 1999 Feb 20;353(9153):611-6
10030325
J Clin Hypertens (Greenwich). 2004 Nov;6(11):614-20
15538094
Hypertension. 2005 Jan;45(1):46-52
15583076
Am J Cardiovasc Drugs. 2005;5(1):17-22
15631534
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11
15734614
J Am Coll Cardiol. 2005 Mar 15;45(6):813-27
15766813
Arch Intern Med. 2005 May 23;165(10):1147-52
15911728
Stroke. 2005 Jun;36(6):1218-26
15879332
Expert Opin Emerg Drugs. 2005 Nov;10(4):729-45
16262560
Am J Hypertens. 2000 Apr;13(4 Pt 1):418-26
10821345
Pharmacoeconomics. 2001;19(4):337-47
11383751
JAMA. 2002 Sep 18;288(11):1388-95
12234233
JAMA. 2002 Dec 18;288(23):2981-97
12479763
J Hypertens. 2003 May;21(5):875-86
12714861
JAMA. 2003 May 14;289(18):2363-9
12746359
JAMA. 2003 May 21;289(19):2560-72
12748199
JAMA. 2003 May 21;289(19):2534-44
12759325
J Hypertens. 2003 Jun;21(6):1011-53
12777938
BMJ. 2003 Jun 28;326(7404):1419
12829553